Chinese authorities investigate AstraZeneca for data privacy violations and unlicensed medication imports.

AstraZeneca's CEO, Pascal Soriot, announced that Chinese authorities are investigating allegations of illegal activities involving a few current and former employees, including data privacy violations and unlicensed medication imports. The company maintains compliance with Chinese regulations and is cooperating with the investigation. Additionally, AstraZeneca reported findings from a lung cancer drug trial, showing a two-month survival improvement, though results lacked statistical significance.

September 10, 2024
10 Articles